• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6 POS filed by LianBio

    3/12/24 8:30:54 AM ET
    $LIAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIAN alert in real time by email
    F-6 POS 1 e619325_f6pos-lianbio.htm

     

    As filed with the Securities and Exchange Commission on March 12, 2024

    Registration No. 333- 260162

     

     

     

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY

    AMERICAN DEPOSITARY RECEIPTS

     

     

     

    LIANBIO 

    (Exact name of issuer of deposited securities as specified in its charter)

     

     

     

    N/A

    (Translation of issuer’s name into English)

     

     

     

    Cayman Islands 

    (Jurisdiction of incorporation or organization of issuer)

     

     

     

    CITIBANK, N.A.

    (Exact name of depositary as specified in its charter)

     

     

     

    388 Greenwich Street

    New York, New York 10013

    (877) 248 - 4237

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

     

     

     

    Adam Stone

    103 Carnegie Center Drive, Suite 309

    Princeton, NJ 08540

    (609) 486-2308

    (Address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Thomas J. Danielski, Esq.

    Ropes & Gray LLP

    Prudential Tower

    800 Boylston Street

    Boston, MA 02199

    (617) 951-7000

     

    Herman H. Raspe, Esq.

    Patterson Belknap Webb & Tyler LLP

    1133 Avenue of the Americas

    New York, New York 10036

    (212) 336-2301

     

     

     

    It is proposed that this filing become effective under Rule 466: ☐ immediately upon filing.
         
      ☐

    on (Date) at (Time).

     

    If a separate registration statement has been filed to register the deposited shares, check the following box: ☐

     

     

     

     

    EXPLANATORY NOTE

     

    The Registrant hereby deregisters all remaining American Depositary Shares previously registered by this Registration Statement that have not been issued.

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3. EXHIBITS

     

    (a)       Deposit Agreement, dated as of November 3, 2021, by among LianBio (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners from time to time of American Depositary Shares issued thereunder (“Deposit Agreement”) ___ Filed herewith as Exhibit (a).

     

    (b)       Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. ___ None.

     

    (c)       Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

     

    (d)       Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ Previously filed with the with the Securities and Exchange Commission on October 8, 2021 (Reg. No. 333-260162).

     

    (e)       Certificate under Rule 466. ___ None.

     

    (f)       Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

     

    II-1

     

     

    Item 4. UNDERTAKINGS

     

    (a)               The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)               If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among LianBio, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 12th day of March, 2024.

     

     

    Legal entity created by the Deposit Agreement under which the American Depositary Shares registered thereunder are issued, each American Depositary Share representing the right to receive one (1) ordinary share of LianBio

     

    CITIBANK, N.A., solely in its capacity as Depositary 

         
      By: /s/ Joseph Connor
     

     

    Name: Joseph Connor

    Title: Attorney-in-fact

     

    II-3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, LianBio certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Princeton, State of New Jersey, on March 12, 2024.

     

     

    LIANBIO

         
      By: /s/ Adam Stone
     

     

    Name: Adam Stone

    Title: Interim Chief Executive Officer

     

    II-4

     

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brianne Jahn to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 has been signed by the following persons in the following capacities on March 12, 2024.

     

    Signature  
       
    /s/ Adam Stone  

    Adam Stone

    (Principal Executive Officer)

     
       
    /s/ Ehong (Maggie) Gu  

    Ehong (Maggie) Gu

    (Principal Financial/Accounting Officer)

     
       
    /s/ Konstantin Poukalov  

    Konstantin Poukalov

    (Director)  

     
       
    /s/ Adam Stone  

    Adam Stone

    (Director)

     
       
    /s/ Neil Kumar  

    Neil Kumar

    (Director)

     
       
    /s/ Tassos Gianakakos  

    Tassos Gianakakos

    (Director)

     
       
    /s/ Susan Silbermann  

    Susan Silbermann

    (Director)

     
       
    /s/ Wei Wei Chen  

    Wei Wei Chen

    (Director)  

     
       

     

    II-5

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of LianBio has signed this Registration Statement on March 12, 2024.

       

     

    Adam Stone 

    (Authorized U.S. Representative) 

         
      By: /s/ Adam Stone
     

    Name: Adam Stone

    Title: Interim Chief Executive Officer

     

     

     

    Get the next $LIAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIAN

    DatePrice TargetRatingAnalyst
    1/3/2024$5.00 → $3.00Buy → Underperform
    BofA Securities
    12/22/2023$7.00 → $4.00Buy → Hold
    Jefferies
    More analyst ratings

    $LIAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LianBio Appoints Wei Wei Chen to Board of Directors

      SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the company's Board of Directors. "I am pleased to welcome Wei Wei Chen to the LianBio board," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "Her deep knowledge of the Chinese market, combined with her ability to manage business growth and transformation, will be extremely beneficial to LianBio as we grow our team and make strides toward advancing our diverse pipeline of potentially transformative medicines for patients

      4/7/22 8:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LianBio downgraded by BofA Securities with a new price target

      BofA Securities downgraded LianBio from Buy to Underperform and set a new price target of $3.00 from $5.00 previously

      1/3/24 7:58:41 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio downgraded by Jefferies with a new price target

      Jefferies downgraded LianBio from Buy to Hold and set a new price target of $4.00 from $7.00 previously

      12/22/23 7:26:46 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gu Ehong sold $7,513 worth of Ordinary Shares (1,731 units at $4.34) and returned $5,724 worth of Ordinary Shares to the company (17,889 units at $0.32), closing all direct ownership in the company (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      4/11/24 4:10:11 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Poukalov Konstantin exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      2/20/24 5:27:03 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc exercised 72,600 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 38,436 units of Ordinary Shares (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      2/20/24 5:25:28 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LianBio Announces Voluntarily Delisting from Nasdaq

      SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its

      2/28/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Completion of Strategic Review

      SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities

      2/13/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by LianBio (Amendment)

      SC 13D/A - LianBio (0001831283) (Subject)

      2/29/24 7:45:48 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by LianBio

      SC 13D - LianBio (0001831283) (Subject)

      11/30/23 5:08:48 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by LianBio

      SC 13G - LianBio (0001831283) (Subject)

      11/1/23 4:00:16 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    SEC Filings

    See more
    • SEC Form 15-12G filed by LianBio

      15-12G - LianBio (0001831283) (Filer)

      3/21/24 8:00:10 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by LianBio

      EFFECT - LianBio (0001831283) (Filer)

      3/13/24 12:15:04 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form F-6 POS filed by LianBio

      F-6 POS - LianBio (0001831283) (Subject)

      3/12/24 8:30:54 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Financials

    Live finance-specific insights

    See more
    • LianBio Announces Voluntarily Delisting from Nasdaq

      SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its

      2/28/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Completion of Strategic Review

      SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities

      2/13/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients

      • Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a live virtual analyst and investor event to review EXPLORER-CN topline data and the China market opportunity for mavacamten on Monday, May 1 at 8:00 a.m. EDT / 8:00 p.m. CST SHANGHAI, China and PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to pati

      4/26/23 8:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care